Home/ Stocks/ AUTL

Autolus Therapeutics plc American Depositary Share

AUTL XNAS

$1.57 +0.02 (+1.24%) ▲ 15-min delayed

Open

$1.62

High

$1.64

Low

$1.55

Volume

1.20M

Market Cap

$417.84M

About Autolus Therapeutics plc American Depositary Share

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 752 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$75.39M	$-287,528,000	$-1.08
FY 2025	$75.39M	$-287,528,000	$-1.08
Q3 2025	$21.19M	$-79,118,000	$-0.30
Q2 2025	$20.92M	$-47,917,000	$-0.18

Related Market News

No specific coverage for AUTL yet. Check out our latest market news or earnings calendar.

Get AUTL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Autolus Therapeutics plc American Depositary Share.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.